Advances in the Management of Migraine

Migraine is currently understood as a complex variable disorder of nervous system function rather than simply a vascular headache. For most patients it is a lifelong condition with variable expression over time. Patients with migraine often experience significant disability. In recent years new pharmacologic strategies for migraine have emerged that address some of the challenges associated with conventional therapies. These include agents that target calcitonin gene-related peptide (CGRP) a neuropeptide central to migraine pathophysiology that has been observed to increase during a migraine. This program addresses the pathophysiology of migraine and the role of the CGRP pathway diagnosis and treatment of acute migraine treatments to prevent migraine including anti-CGRP therapies and how to integrate CGRP inhibitors into clinical practice.

Share

Program Content

Activities

Advances in the Management of Migraine
Advances in the Management of Migraine: The Role of CGRP Inhibitors
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2020

Expires: January 22, 2021

Faculty

cover img faculity

Rebecca C. Burch, MD, FAHS

Assistant Professor
Harvard Medical School
Department of Neurology
Associate Neurologist
Brigham and Women’s Hospital
Boston, Massachusetts

Supporters

This activity is supported by an educational grant from

Allergan Inc